title: Indications for a more aggressive disease process in newly diagnosed insulin-dependent diabetic children in northern than in southern Europe.
abstract: Finland and Sweden have the highest incidence of insulin-dependent diabetes in children in the world, about 3-4 times that of countries in the Mediterranean area, with the exception of Sardinia. We have collected information from several European clinics and from Pittsburgh, USA, in order to find out whether this difference incidence is associated with corresponding differences of the disease pattern. Patients in Finland or Sweden ('North') and Pittsburgh were younger (< 10 years old) at diagnosis compared with those in the other clinics in Europe (P < 0.05 versus P < 0.02). In the North, boys were in excess (58%) in contrast to France (40%) and Pittsburgh (46%). Patients in the North had a shorter duration of symptoms (< 8 days; P < 0.001) and higher blood glucose (> 20 mmol/l; P < 0.05) than those attending the other European clinics. Irrespective of age, there were more ICA-positive patients in the North (94%) than in Berlin-Vienna (67%; P < 0.01) or in France (70%; P < 0.01). There was a tendency for non-diabetic parents and siblings in the North to have lower C-peptide values (< 0.26 pmol/ml) at the time of diagnosis of the proband and to be ICA-positive more often than relatives in the other European clinics. The seasonal variation of diagnosis showed no obvious geographical differences, with recorded diagnosis always lowest during the summer. We conclude that certain factors seem to cause not only a high incidence of diabetes in children in Finland and Sweden but perhaps also a more aggressive early disease process.
authors.affiliation: Department of Paediatrics, University Hospital, Linköping, Sweden.
authors.forename: U
authors.initials: U
authors.lastname: Samuelsson
authors.forename: J
authors.initials: J
authors.lastname: Ludvigsson
authors.forename: G F
authors.initials: GF
authors.lastname: Bottazzo
authors.forename: M
authors.initials: M
authors.lastname: Shattock
authors.forename: S
authors.initials: S
authors.lastname: Adolfsson
authors.forename: D
authors.initials: D
authors.lastname: Becker
authors.forename: E
authors.initials: E
authors.lastname: Cacciari
authors.forename: F
authors.initials: F
authors.lastname: Chiarelli
authors.forename: G
authors.initials: G
authors.lastname: Chiumello
authors.forename: I
authors.initials: I
authors.lastname: Deschamps
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D001317:Austria; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology*; D005190:Family; D005260:Female; D005387:Finland / Q000453:epidemiology; D005602:France; D005843:Geography; D005858:Germany; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007515:Islets of Langerhans / Q000276:immunology; D007558:Italy; D008297:Male; D010414:Pennsylvania; D012621:Seasons; D012727:Sex Characteristics; D013548:Sweden / Q000453:epidemiology
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D001786:Blood Glucose; D002096:C-Peptide; C024211:islet cell antibody